ATLANTA--(BUSINESS WIRE)--Inhibitex, Inc. (NASDAQ:INHX), a biopharmaceutical company focused on the development of products to treat and prevent serious infectious diseases, announced today that it has completed its initial Phase I clinical trial of FV-100, a nucleoside analogue being developed to treat shingles. The blinded, placebo-controlled single ascending dose study, which was conducted in the United States under an exploratory Investigational New Drug Application (IND), evaluated the safety and pharmacokinetics of three oral doses of FV-100 (10, 20 and 40 mg) in healthy volunteers. Each of the three dose cohorts consisted of six subjects that received FV-100 and two that received placebo.
